AVI BioPharma, Inc. (AVII) Misses Q1 EPS by 6c

AVI BioPharma, Inc. (NASDAQ: AVII) reported Q1 EPS of ($0.13), $0.06 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $11.2 million versus the consensus estimate of $11.05 million.

For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CrowdStrike shares jump on earnings beat, raised outlook
• Alcon prices €500M senior notes due 2033
• Okta, Inc. (OKTA) Tops Q2 EPS by 8c; offers guidance